Rachel M. Layman, Patricia LoRusso, Toru Mukohara, Yeon Hee Park, Hope S. Rugo, Fengting Yan, Seock-Ah Im, Kan Yonemori, David Sommerhalder, Toshinari Yamashita, Gun Min Kim, Fumikata Hara, Sung-Bae Kim, Shusen Wang, Jee Hyun Kim, Shreya Badhrinarayanan, Athanasia Skoura, Sean Kent, Meng Li, Erika P. Hamilton. "Long-term safety results and adverse event (AE) management recommendations in patients with ER+/HER2− metastatic breast cancer (mBC) receiving prifetrastat, a first-in-class KAT6 inhibitor, at the recommended phase 3 dose (RP3D) of 5 mg once-daily (QD).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.1068